Evidence map›Paper›PMID 40256674›Full record

ArticleBreast care (Basel, Switzerland)2025

Targeted Axillary Dissection Using Surgical Marker Navigation after Neoadjuvant Systemic Treatment in Breast Cancer Patients: A Single-Center Experience.

Daniel Egle, Christine Brunner, Magdalena Ritter, Verena Wieser, Katharina Knoll, Birgit Amort, Afshin Soleiman, Heidelinde Fiegl, Christian Marth, Carmen Albertini and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniel EgleDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Christine BrunnerDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Magdalena RitterDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Verena WieserDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Katharina KnollDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Birgit AmortDepartment of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
Afshin SoleimanINNPATH, Institute of Pathology, Tirol Kliniken Innsbruck, Innsbruck, Austria.
Heidelinde FieglDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Christian MarthDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Carmen AlbertiniDepartment of Obstetrics and Gynaecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Innsbruck, Austria.
Rupert BartschDivision of Oncology, Department of Medicine, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In early-stage breast cancer with initially positive axillary lymph nodes, reliable assessment of the involvement of the axilla is important because of the prognostic importance of lymph node metastases. After neoadjuvant chemotherapy (NACT), targeted axillary dissection (TAD), including sentinel lymph node biopsy and primarily involved lymph nodes, is currently regarded as the standard of care. The target lymph node must be marked using a clip/marker and later localized using a reliable guidance technique to identify the node, to avoid the indication of axillary lymph node dissection. Methods: The present study aimed to evaluate retrospective data collected from April 25, 2022, until March 30, 2023, on a consecutive series of patients, to determine the efficacy and safety of using the Sirius Pintuition GPSDetect Results: This consecutive case series shows that identification of the target node with surgical marker navigation is feasible and safe, with a 100% identification rate at surgery, in a population of 20 patients with histologically verified axillary lymph node involvement before NACT. Conclusion: Magnetically guided localization systems may therefore be a valid alternative to ultrasound-guided wire placement. The data highlight the practicality of the magnetically guided approach, which potentially contributes to a reduction in treatment-related morbidity by avoiding unnecessary axillary lymph node dissection.

Indexed as

AxillaChemotherapyImaging techniqueMagneticsMargins of excisionNeoplasmNeoplasm gradingTherapy

Identifiers

PMID40256674
PMCPMC12005687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.